TAG HIV Basic Science, Vaccines, and Cure Project Blog
By Richard Jefferys, Project Director at Treatment Action Group (TAG).
recent posts
- In The News: CAR-T Cells for HIV
- TAG’s HIV Cure-Related Clinical Research Listing: Background on the March 2026 Update
- TAG’s HIV Cure-Related Clinical Research Listing: Background on the February 2026 Update
- TAG’s HIV Cure-Related Clinical Research Listing: Background on the December 2025 and January 2026 Updates
- TAG’s HIV Cure-Related Clinical Research Listing: Background on the November 2025 Update
Category: Immune-based therapies
-
For August 2025, there were eight updates to the TAG listing. New Additions A study sponsored by the ANRS RHIVIERA project in France plans to investigate the JAK1/JAK2 Inhibitor baricitinib and the mTOR Inhibitor sirolimus in people who started antiretroviral therapy (ART) soon after HIV acquisition. Baricitinib is also being tested in several other ongoing…
-
The were ten updates to the TAG listing in July 2025. New Additions Four newly registered HIV cure-related studies were added: Oxford University in the UK is sponsoring AbVax, a phase II combination trial that will administer therapeutic vaccines designed to induce T cell responses against HIV plus two broadly neutralizing antibodies (bNAbs), teropavimab…
-
The June 2025 update to TAG’s listing features 11 changes. New Additions Two studies were added: The ACTG has registered a new trial of dual broadly neutralizing antibodies (bNAbs), VRC07-523LS and PGT121.414.LS, in people who initiated antiretroviral therapy (ART) during acute HIV infection. The protocol includes an analytical treatment interruption (ATI) to assess whether receipt…
-
For March, April, and May 2025, there were 38 updates to entries in TAG’s listing. The majority involved the addition of links to results presented at the annual Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco. As is covered further below, this period has seen a horrific and unprecedented political attack on scientific…
-
A total of eight changes were made to TAG’s listing for the first monthly update of 2024. New Additions One new study has been added from the Pan African Clinical Trials Registry: Scientists affiliated with the Centre for the AIDS Programme of Research in South Africa (CAPRISA) are launching a phase I cure-related trial investigating…
-
The April 2023 update to TAG’s HIV cure-related clinical research listing adds five new studies, two involving interventions and three observational. Researchers at the University of Sao Paulo General Hospital in Brazil are opening a study of a therapeutic HIV vaccine based on dendritic cells (DCs). DCs are immune system cells tasked with initiating the…
-
The February 15, 2023 update to TAG’s HIV cure-related clinical research listing includes three newly registered studies: The AIDS Clinical Trials Group (ACTG) is initiating a study of two long-acting broadly neutralizing antibodies (bNAbs) named VRC07-523LS and PGT121.414.LS combined with antiretroviral therapy (ART) in people with acute (recently acquired) HIV infection. The trial has yet…
-
One of the most widely discussed and publicized ideas for targeting the HIV reservoir is “kick and kill” or “shock and kill.” The aim is to kick dormant, latent HIV into revealing itself so the cells that contain the virus are visible to the immune system; the kill aspect involves trying to enhance the immune…
-
Among the most newsworthy presentations at CROI 2018 earlier this year was Dan Barouch’s description of a study involving a toll-like receptor 7 (TLR7) agonist combined with a broadly neutralizing antibody (bNAb) in SHIV-infected macaques (see contemporary coverage by AIDSMap, i-Base and POZ Magazine). The results have now been published in the journal Nature. The…
-
An important goal in HIV cure research is the identification of immune responses that might be induced or enhanced to promote clearance of virus-infected cells. The main focus of this work has been on adaptive immunity—components of the immune system that can specifically recognize HIV, which include CD4 T cells, CD8 T cells, B cells…